rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NVCT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Nuvectis Pharma, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceNVCT
      Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...

      Nuvectis Pharma Inc (NVCT) outlined a bold late-stage pipeline with ciprocapan and NXP200, a cash runway into 2029, and multiple near-term catalysts despite FDA and competitive uncertainties.

      Nov 4Yahoo FinanceNVCT
      Nuvectis Pharma Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceNVCT
      Nuvectis (NVCT) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 4The Globe and MailNVCT
      Nuvectis Pharma Q3 2026 Earnings Call Transcript
      Nov 4BenzingaNVCT
      Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
      Nov 4Yahoo FinanceNVCT
      Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
      Nov 2Yahoo FinanceNVCT
      Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVC
      Oct 26BenzingaNVCT
      Nuvectis reports phase 1b data for glioma drug candidate NXP200
      Oct 26Investing.comNVCT
      Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
      Sep 25Investing.comNVCT
      Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead

      WSW, NY, September 25th, 2026, FinanceWireThree months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-stage program. Today it holds ex-China rights to the world's first

      Sep 25BenzingaNVCT
      Nuvectis’ NXP200 receives breakthrough therapy status in China
      Sep 24Investing.comNVCT
      Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
      Sep 24Yahoo FinanceNVCT
      Nuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)
      Sep 18Seeking AlphaNVCT
      Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out
      Sep 14Investing.comNVCT
      Nuvectis at Cantor healthcare conference: betting on factor B
      Sep 11Investing.comNVCT
      Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)
      Sep 3BenzingaNVCT
      Nuvectis Pharma To Participate in Upcoming Investor Conferences

      Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast li

      Sep 3Yahoo FinanceNVCT
      Lucid Capital Markets initiates Nuvectis Pharma stock with buy rating
      Sep 1Investing.comNVCT

      This is the newest page. Registered accounts read further back.